Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVENTYL vs ASENDIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Major depressive disorder (endogenous depression)
Treatment of depression (neurotic and psychotic depression),Off-label: anxiety disorders, agitation in schizophrenia
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Extensively metabolized in the liver by cytochrome P450 enzymes (CYP2D6, CYP1A2, CYP2C19) via hydroxylation, N-demethylation, and N-oxidation; active metabolite: 10-hydroxynortriptyline. Metabolites are conjugated and excreted in urine.
Primarily hepatic via CYP450 enzymes, notably CYP2D6 and CYP3A4. Major metabolites: 7-hydroxyamoxapine (active) and 8-hydroxyamoxapine.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
90-95% bound primarily to albumin.
90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
15-30 L/kg; indicates extensive tissue penetration.
Apparent volume of distribution is 8-10 L/kg, indicating extensive tissue distribution and accumulation in peripheral compartments.
Oral: 30-60% due to first-pass metabolism.
Oral bioavailability is approximately 70-80% due to first-pass metabolism. No parenteral formulation is available; only oral route.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 50% of normal dose or every 12 hours.
Cr Cl 30-60 m L/min: reduce dose by 25-50%. Cr Cl <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce dose by 75% with monitoring.
Child-Pugh class C: contraindicated. Child-Pugh class B: reduce dose by 50%.
Children 6-12 years: 10-30 mg/day in divided doses; >12 years: 25-50 mg/day in divided doses, maximum 100 mg/day. Weight-based: 1-2 mg/kg/day.
Not recommended for use in children due to lack of safety data.
Initial dose 10-25 mg/day in divided doses, titrate slowly to maximum 100 mg/day; use with caution due to anticholinergic effects.
Initial dose 25 mg twice daily, increase slowly with close monitoring due to increased sensitivity and anticholinergic effects.
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Nortriptyline is not approved for use in pediatric patients.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality: Monitor for worsening depression and suicidal thoughts, especially in young adults.,Cardiotoxicity: Risk of QT prolongation, arrhythmias, and sudden death; use with caution in patients with cardiovascular disease.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Anticholinergic effects: Use caution in patients with prostatic hypertrophy, narrow-angle glaucoma, or urinary retention.,Seizures: May lower seizure threshold.,Electroconvulsive therapy (ECT): Avoid concomitant use.,Hepatic impairment: Use with caution; metabolism may be reduced.,Hyperthyroidism: May potentiate cardiac toxicity.
Suicidality risk,Neuroleptic malignant syndrome,Tardive dyskinesia,Seizure threshold lowering,Cardiotoxicity (QT prolongation, arrhythmias),Anticholinergic effects,Hypotension,Hepatic impairment
Hypersensitivity to nortriptyline or any component of the formulation.,Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.,Acute recovery phase after myocardial infarction.,Concomitant use with cisapride, due to risk of QT prolongation.
Hypersensitivity to amoxapine or any component,Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Acute recovery phase after myocardial infarction,Known alcohol or barbiturate intoxication
Avoid tyramine-rich foods (aged cheeses, cured meats, sauerkraut, soy products, tap beers) as concomitant use with MAOIs is contraindicated. However, nortriptyline itself has minimal tyramine interaction. Grapefruit juice may increase nortriptyline levels; avoid or limit intake. High-fiber foods may reduce absorption; take with a full glass of water.
Avoid ethanol; may cause additive CNS depression. No specific food interactions; however, taking with food may reduce GI upset.
First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (irritability, feeding disorders) and anticholinergic effects (ileus, tachycardia).
ASENDIN (amoxapine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Risk of congenital malformations cannot be excluded. Second and third trimesters: Neonates may exhibit transient withdrawal symptoms (jitteriness, respiratory depression) or serotonin syndrome if used near term. Avoid use unless benefit outweighs risk.
Excreted in human milk; M/P ratio unknown. Limited data suggests low levels; use with caution, monitor infant for sedation and anticholinergic effects.
Amoxapine is excreted in human breast milk. M/P ratio is unknown. Due to limited safety data, breastfeeding is not recommended during therapy. If essential, monitor infant for sedation, poor feeding, and weight loss.
Increased hepatic metabolism in pregnancy may require dose adjustment; start at low end of dosing range, titrate based on response and tolerability.
No specific dose adjustments are established. Due to increased plasma volume and hepatic metabolism in pregnancy, therapeutic drug monitoring is recommended to ensure efficacy and avoid toxicity. Initiate at low doses and titrate based on clinical response and serum concentrations if available.
Aventyl (nortriptyline) is a secondary amine tricyclic antidepressant with less anticholinergic and sedative effects than tertiary amines like amitriptyline. It exhibits a narrow therapeutic window; therapeutic plasma levels are 50-150 ng/m L. Use with caution in patients with cardiovascular disease due to risk of QT prolongation. Avoid abrupt discontinuation to prevent withdrawal-like symptoms. Monitoring of plasma levels is recommended in elderly and those with hepatic impairment.
Asendin (amoxapine) is a dibenzoxazepine antidepressant with a 7-hydroxy metabolite that confers dopamine blockade, giving it a unique antipsychotic profile. Monitor for extrapyramidal symptoms and tardive dyskinesia, especially in elderly patients. Due to significant anticholinergic effects, use cautiously in patients with benign prostatic hyperplasia, narrow-angle glaucoma, or cognitive impairment. Avoid coadministration with MAOIs; allow at least 14 days between therapies. May cause a false-positive urine amphetamine screen due to structural similarity.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of serotonin syndrome (agitation, hallucinations, fever) or suicidal thoughts.,May take 2-4 weeks to see full therapeutic effect.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,Store at room temperature away from moisture and light.
Take exactly as prescribed; do not stop abruptly or adjust dose without consulting your doctor.,Avoid alcohol and other CNS depressants as they can increase drowsiness and dizziness.,May cause dry mouth; use sugar-free gum or candy to alleviate.,Report any unusual movements, especially of the face or tongue, or severe muscle stiffness.,May increase sensitivity to sunlight; use sunscreen and protective clothing.,Inform all healthcare providers you are taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVENTYL vs ASENDIN, answered by our medical review team.
AVENTYL is a Tricyclic Antidepressant that works by Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.. ASENDIN is a Tricyclic Antidepressant that works by Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVENTYL and ASENDIN depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVENTYL is: Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.. The standard adult dose of ASENDIN is: 50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVENTYL and ASENDIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVENTYL is classified as Category C. First trimester: Limited human data, animal studies show no consistent teratogenicity; avoid due to risk of fetal tachycardia. Second/third trimester: Risk of neonatal withdrawal (. ASENDIN is classified as Category C. ASENDIN (amoxapine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Risk of congenital malformatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.